Fosun Pharma
Fosun Licenses Immunology Asset FXS6837 to Sitala in $670M Deal
Fosun Pharma; Sitala; FXS6837; immunology; license agreement; autoimmune diseases; biotech; pharmaceuticals; $670 million
Gilead’s Kite Unit Exits China CAR-T Joint Venture with Fosun
Gilead Sciences, Kite Pharma, Fosun Pharma, CAR-T cell therapy, joint venture, China, Yescarta
Gilead’s Kite Terminates China Cell Therapy Joint Venture with Fosun Pharma
Gilead Sciences, Kite Pharma, Fosun Pharma, cell therapy, joint venture, China, CAR-T therapy, Yescarta